BioVie, Inc. (BIVI)

NASDAQ: BIVI · IEX Real-Time Price · USD
5.49
-2.56 (-31.80%)
At close: Dec 2, 2022 4:00 PM
5.64
+0.15 (2.73%)
After-hours: Dec 2, 2022 7:59 PM EST
-31.8%
Market Cap 245.79M
Revenue (ttm) n/a
Net Income (ttm) -30.96M
Shares Out 27.21M
EPS (ttm) -6.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,164,291
Open 7.94
Previous Close 8.05
Day's Range 4.11 - 7.94
52-Week Range 1.33 - 8.26
Beta 2.67
Analysts Buy
Price Target 9.18 (+67.2%)
Earnings Date Nov 9, 2022

About BIVI

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer'... [Read more]

Industry Biotechnology
Founded 2013
Employees 13
Stock Exchange NASDAQ
Ticker Symbol BIVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for BIVI stock is "Buy." The 12-month stock price forecast is 9.18, which is an increase of 67.21% from the latest price.

Price Target
$9.18
(67.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioVie's Phase 3 Trial Assessing NE3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients

Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace

4 days ago - GlobeNewsWire

Are Medical Stocks Lagging BioVie (BIVI) This Year?

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

1 week ago - Zacks Investment Research

BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatmen...

CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurologic...

2 weeks ago - GlobeNewsWire

Wall Street Analysts Think BioVie Inc. (BIVI) Could Surge 84%: Read This Before Placing a Bet

The mean of analysts' price targets for BioVie Inc. (BIVI) points to an 84% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

2 weeks ago - Zacks Investment Research

Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

3 weeks ago - Zacks Investment Research

BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurologic...

1 month ago - GlobeNewsWire

BioVie's Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

Topline Data Expected December 2022 Topline Data Expected December 2022

1 month ago - GlobeNewsWire

BioVie Issues Letter to Shareholders

CARSON CITY, Nev., Oct. 04, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced l...

1 month ago - GlobeNewsWire

BioVie to Participate in Cantor Fitzgerald's Neurology & Psychiatry Conference

RENO, Nev., Sept. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver ...

2 months ago - GlobeNewsWire

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / September 15, 2022 / RedChip Companies will air a new interview with BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug the...

2 months ago - Accesswire

BioVie (BIVI) Stock Pops on Positive Alzheimer's Trial Results

In a fresh press release from this morning, BioVie (NASDAQ: BIVI ) disclosed top-line results from a Phase 2 clinical trial for its Alzheimer's disease treatment, NE3107. The results were largely positi...

2 months ago - InvestorPlace

BioVie shares soar 19% premarket after company announces positive results from Phase 2 trial of Alzheimer's treatment

BioVie Inc. shares BIVI, +22.42% rose 19% in premarket trade Wednesday, after the biotech announced positive results from a Phase 2 trial of its Alzheimer's Disease treatment NE3107. Moving away from th...

2 months ago - Market Watch

BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker a...

BioVie Provides Updates on Other Clinical Programs BioVie Provides Updates on Other Clinical Programs

2 months ago - GlobeNewsWire

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver...

5 months ago - GlobeNewsWire

BioVie to Participate at the B. Riley Securities' Neuro & Ophthalmology Conference

CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...

7 months ago - GlobeNewsWire

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurologic...

8 months ago - GlobeNewsWire

BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver ...

8 months ago - GlobeNewsWire

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson's Disease

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver di...

10 months ago - GlobeNewsWire

BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver d...

11 months ago - GlobeNewsWire

BioVie Announces Partnership with the American Liver Foundation

Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie's Phase 2b Study of BIV201 for Refractory Ascites Campaign to Improve Education on Ascites Due to Liver Cirr...

11 months ago - GlobeNewsWire

BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Op...

RENO, Nev., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and ...

1 year ago - GlobeNewsWire

BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical T...

Thursday, November 11th @ 1:00pm ET Thursday, November 11th @ 1:00pm ET

1 year ago - GlobeNewsWire

BioVie Announces the Appointment of a New Chief Medical Officer

Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Over...

1 year ago - GlobeNewsWire

Why Did BioVie Shares Jump 21% Today?

The FDA has signed off BioVie Inc's (NASDAQ: BIVI) Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients. The NM201 study is a double-blind, placebo-controlled, s...

1 year ago - Benzinga

BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107's Pro-motoric Activity in Parkinson's ...

SANTA MONICA, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurolo...

1 year ago - GlobeNewsWire